CA2096633A1 - Measles virus recombinant poxvirus vaccine - Google Patents
Measles virus recombinant poxvirus vaccineInfo
- Publication number
- CA2096633A1 CA2096633A1 CA002096633A CA2096633A CA2096633A1 CA 2096633 A1 CA2096633 A1 CA 2096633A1 CA 002096633 A CA002096633 A CA 002096633A CA 2096633 A CA2096633 A CA 2096633A CA 2096633 A1 CA2096633 A1 CA 2096633A1
- Authority
- CA
- Canada
- Prior art keywords
- virus
- plasmid
- recombinant
- dna
- vaccinia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000712079 Measles morbillivirus Species 0.000 title claims abstract description 57
- 229940024231 poxvirus vaccine Drugs 0.000 title description 3
- 241000700618 Vaccinia virus Species 0.000 claims abstract description 75
- 108020004414 DNA Proteins 0.000 claims abstract description 55
- 241001465754 Metazoa Species 0.000 claims abstract description 40
- 229960005486 vaccine Drugs 0.000 claims abstract description 35
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 33
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 33
- 241000178270 Canarypox virus Species 0.000 claims abstract description 25
- 241000712045 Morbillivirus Species 0.000 claims abstract description 21
- 230000028993 immune response Effects 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 208000000655 Distemper Diseases 0.000 claims abstract description 6
- 208000014058 canine distemper Diseases 0.000 claims abstract description 5
- 230000001939 inductive effect Effects 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 36
- 230000004927 fusion Effects 0.000 claims description 34
- 230000006798 recombination Effects 0.000 claims description 31
- 238000005215 recombination Methods 0.000 claims description 28
- 241000700663 Avipoxvirus Species 0.000 claims description 7
- 101900237959 Measles virus Hemagglutinin glycoprotein Proteins 0.000 claims description 7
- 101710121925 Hemagglutinin glycoprotein Proteins 0.000 claims description 3
- 241000282472 Canis lupus familiaris Species 0.000 abstract description 44
- 239000013612 plasmid Substances 0.000 description 140
- 206010046865 Vaccinia virus infection Diseases 0.000 description 76
- 208000007089 vaccinia Diseases 0.000 description 76
- 239000012634 fragment Substances 0.000 description 74
- 108090000623 proteins and genes Proteins 0.000 description 60
- 101710154606 Hemagglutinin Proteins 0.000 description 58
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 58
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 58
- 101710176177 Protein A56 Proteins 0.000 description 58
- 210000004027 cell Anatomy 0.000 description 57
- 241000700605 Viruses Species 0.000 description 53
- 238000012217 deletion Methods 0.000 description 47
- 230000037430 deletion Effects 0.000 description 47
- 238000011081 inoculation Methods 0.000 description 43
- 239000000185 hemagglutinin Substances 0.000 description 42
- 201000005505 Measles Diseases 0.000 description 41
- 241000712083 Canine morbillivirus Species 0.000 description 37
- 241000283973 Oryctolagus cuniculus Species 0.000 description 32
- 239000013598 vector Substances 0.000 description 32
- 108091034117 Oligonucleotide Proteins 0.000 description 30
- 101150039660 HA gene Proteins 0.000 description 29
- 238000010276 construction Methods 0.000 description 27
- 108010005774 beta-Galactosidase Proteins 0.000 description 25
- 241000588724 Escherichia coli Species 0.000 description 23
- 230000003472 neutralizing effect Effects 0.000 description 23
- 210000003501 vero cell Anatomy 0.000 description 22
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 19
- 230000001681 protective effect Effects 0.000 description 19
- 230000004044 response Effects 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 19
- 102000005936 beta-Galactosidase Human genes 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 17
- 230000029087 digestion Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 108010017826 DNA Polymerase I Proteins 0.000 description 16
- 102000004594 DNA Polymerase I Human genes 0.000 description 16
- 238000003780 insertion Methods 0.000 description 16
- 230000037431 insertion Effects 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 238000001114 immunoprecipitation Methods 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 15
- 230000002238 attenuated effect Effects 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 241000700198 Cavia Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000010790 dilution Methods 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- 238000012809 post-inoculation Methods 0.000 description 12
- 101150060895 I4L gene Proteins 0.000 description 11
- 230000000405 serological effect Effects 0.000 description 11
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 108700026244 Open Reading Frames Proteins 0.000 description 10
- 101150034814 F gene Proteins 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 230000036039 immunity Effects 0.000 description 9
- 230000036961 partial effect Effects 0.000 description 9
- 241000282693 Cercopithecidae Species 0.000 description 8
- 239000013553 cell monolayer Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 7
- 101150039990 B13R gene Proteins 0.000 description 7
- 101150071286 SPI-2 gene Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000007910 cell fusion Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000002703 mutagenesis Methods 0.000 description 7
- 231100000350 mutagenesis Toxicity 0.000 description 7
- 238000006386 neutralization reaction Methods 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
- 108091081024 Start codon Proteins 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 241000700199 Cavia porcellus Species 0.000 description 5
- 206010037742 Rabies Diseases 0.000 description 5
- 108020004440 Thymidine kinase Proteins 0.000 description 5
- 230000003141 anti-fusion Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 230000002008 hemorrhagic effect Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 101710112753 A-type inclusion protein A25 homolog Proteins 0.000 description 4
- 238000012286 ELISA Assay Methods 0.000 description 4
- 241000726306 Irus Species 0.000 description 4
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 4
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 4
- 101150003725 TK gene Proteins 0.000 description 4
- 101100534084 Vaccinia virus (strain Copenhagen) B14R gene Proteins 0.000 description 4
- 101100004092 Vaccinia virus (strain Western Reserve) VACWR196 gene Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000035931 haemagglutination Effects 0.000 description 4
- 239000013615 primer Substances 0.000 description 4
- 238000009589 serological test Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108060002716 Exonuclease Proteins 0.000 description 3
- 241000700662 Fowlpox virus Species 0.000 description 3
- 101150082239 G gene Proteins 0.000 description 3
- 208000004068 Morbillivirus Infections Diseases 0.000 description 3
- 108020005038 Terminator Codon Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 102000013165 exonuclease Human genes 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 230000008774 maternal effect Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 241000271566 Aves Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 208000000666 Fowlpox Diseases 0.000 description 2
- 206010025327 Lymphopenia Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100277251 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HEM12 gene Proteins 0.000 description 2
- 241000282695 Saimiri Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 108091008053 gene clusters Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 229940124590 live attenuated vaccine Drugs 0.000 description 2
- 229940023012 live-attenuated vaccine Drugs 0.000 description 2
- 231100001023 lymphopenia Toxicity 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 238000012808 pre-inoculation Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012770 revaccination Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 238000006677 Appel reaction Methods 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000701101 Canine adenovirus 1 Species 0.000 description 1
- 241000701114 Canine adenovirus 2 Species 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 102100034330 Chromaffin granule amine transporter Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000641221 Homo sapiens Chromaffin granule amine transporter Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 238000012218 Kunkel's method Methods 0.000 description 1
- HCIHJOTZGZSMLV-UHFFFAOYSA-N Lutinine Natural products O=C1C(=Nc2ccccc2)C=C(Nc3ccccc3)c4ccccc14 HCIHJOTZGZSMLV-UHFFFAOYSA-N 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000025174 PANDAS Diseases 0.000 description 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 241001147385 Potos flavus Species 0.000 description 1
- 241000282696 Saimiri sciureus Species 0.000 description 1
- 241000287231 Serinus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 241000700622 Vaccinia virus Copenhagen Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 101150061325 mv gene Proteins 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000017960 syncytium formation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62161490A | 1990-11-20 | 1990-11-20 | |
| US621,614 | 1990-11-20 | ||
| US77686791A | 1991-10-22 | 1991-10-22 | |
| US776,867 | 1991-10-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2096633A1 true CA2096633A1 (en) | 1992-05-21 |
Family
ID=27089007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002096633A Abandoned CA2096633A1 (en) | 1990-11-20 | 1991-11-20 | Measles virus recombinant poxvirus vaccine |
Country Status (12)
| Country | Link |
|---|---|
| JP (2) | JP3617668B2 (it) |
| AU (1) | AU1253892A (it) |
| BE (1) | BE1005908A5 (it) |
| CA (1) | CA2096633A1 (it) |
| CH (1) | CH683921A5 (it) |
| DE (2) | DE4192786B4 (it) |
| FR (1) | FR2669346B1 (it) |
| GB (2) | GB2283021B (it) |
| IE (2) | IE71643B1 (it) |
| IT (1) | IT1252687B (it) |
| NL (2) | NL195058C (it) |
| WO (1) | WO1992008789A1 (it) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5833975A (en) * | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US7767449B1 (en) | 1981-12-24 | 2010-08-03 | Health Research Incorporated | Methods using modified vaccinia virus |
| US5505941A (en) * | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US6248333B1 (en) | 1990-04-04 | 2001-06-19 | Health Research Inc. | Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD) |
| US5756102A (en) * | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
| AU672581B2 (en) * | 1991-03-07 | 1996-10-10 | Virogenetics Corporation | Immunodeficiency virus recombinant poxvirus vaccine |
| KR100242671B1 (ko) * | 1991-03-07 | 2000-03-02 | 고돈 에릭 | 유전학적으로 처리한 백신 균주 |
| US5989561A (en) * | 1991-03-07 | 1999-11-23 | Virogenetics Corporation | Recombinant poxvirus-calicivirus rabbit hemorrhagic disease virus (RHDV) compositions and uses |
| WO1992016616A1 (en) * | 1991-03-20 | 1992-10-01 | Virogenetics Corporation | Malaria recombinant poxvirus vaccine |
| US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| CN1089370C (zh) * | 1994-12-08 | 2002-08-21 | 中国预防医学科学研究院病毒学研究所 | 表达麻疹病毒l4株血凝素及融合蛋白基因的重组痘苗病毒 |
| WO1997028265A1 (en) * | 1996-02-05 | 1997-08-07 | University Of Massachusetts Medical Center | Measles immunization by dna transcription unit inoculation |
| US6211165B1 (en) | 1997-05-09 | 2001-04-03 | The Trustees Of The University Of Pennsylvania | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
| EP1095948A1 (en) * | 1999-10-28 | 2001-05-02 | Universitätsklinikum Freiburg | Idiotype vaccines |
| DK1372710T3 (da) | 2001-03-08 | 2010-01-18 | Us Gov Health & Human Serv | MVA der udtrykker modificeret HIV-kappe-, Gag- og Pol-gener |
| AR052743A1 (es) * | 2006-04-11 | 2007-03-28 | Inst Nac De Tecnologia Agropec | Vector plasmidico de transferencia y virus canarypox recombinante |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2617715B1 (fr) * | 1987-07-07 | 1990-08-31 | Transgene Sa | Vecteur viral et adn recombinant codant pour une ou des proteines de surface (ha et/ou f) d'un morbillivirus, culture cellulaire infectee, proteines obtenues, vaccin et anticorps obtenus |
| DE10399032I1 (de) * | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
| FR2632863B2 (fr) * | 1987-10-29 | 1990-08-31 | Transgene Sa | Virus du fowlpox recombinant et vaccins derives de ces virus |
| JPH01218590A (ja) * | 1988-02-29 | 1989-08-31 | Toa Nenryo Kogyo Kk | 組換ワクチニアウイルスを用いたリンダペスト（牛疫）ウイルスワクチン |
-
1991
- 1991-11-13 IE IE960091A patent/IE71643B1/en not_active IP Right Cessation
- 1991-11-13 IE IE396091A patent/IE68404B1/en not_active IP Right Cessation
- 1991-11-19 FR FR9114256A patent/FR2669346B1/fr not_active Expired - Lifetime
- 1991-11-19 BE BE9101066A patent/BE1005908A5/fr not_active IP Right Cessation
- 1991-11-20 JP JP50520492A patent/JP3617668B2/ja not_active Expired - Fee Related
- 1991-11-20 AU AU12538/92A patent/AU1253892A/en not_active Abandoned
- 1991-11-20 GB GB9500214A patent/GB2283021B/en not_active Expired - Lifetime
- 1991-11-20 DE DE4192786A patent/DE4192786B4/de not_active Expired - Lifetime
- 1991-11-20 DE DE4192786T patent/DE4192786T1/de active Pending
- 1991-11-20 CA CA002096633A patent/CA2096633A1/en not_active Abandoned
- 1991-11-20 CH CH2364/92A patent/CH683921A5/fr not_active IP Right Cessation
- 1991-11-20 GB GB9309414A patent/GB2264949B/en not_active Expired - Lifetime
- 1991-11-20 WO PCT/US1991/008703 patent/WO1992008789A1/en active Application Filing
- 1991-11-20 IT ITMI913092A patent/IT1252687B/it active IP Right Grant
- 1991-11-20 NL NL9120026A patent/NL195058C/nl not_active IP Right Cessation
-
2003
- 2003-07-15 NL NL9900036A patent/NL195095C/nl not_active IP Right Cessation
-
2004
- 2004-06-09 JP JP2004170929A patent/JP3824619B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| FR2669346A1 (fr) | 1992-05-22 |
| NL195095C (nl) | 2004-01-21 |
| NL9120026A (nl) | 1993-09-01 |
| JP3617668B2 (ja) | 2005-02-09 |
| BE1005908A5 (fr) | 1994-03-08 |
| DE4192786B4 (de) | 2006-08-24 |
| GB2283021A (en) | 1995-04-26 |
| IE68404B1 (en) | 1996-06-12 |
| IE913960A1 (en) | 1992-05-20 |
| GB9309414D0 (en) | 1993-07-14 |
| IE71643B1 (en) | 1997-02-26 |
| DE4192786T1 (de) | 1994-01-13 |
| GB2264949A (en) | 1993-09-15 |
| IT1252687B (it) | 1995-06-23 |
| AU1253892A (en) | 1992-06-11 |
| GB9500214D0 (en) | 1995-03-01 |
| JPH06502996A (ja) | 1994-04-07 |
| CH683921A5 (fr) | 1994-06-15 |
| NL195058C (nl) | 2003-07-01 |
| JP2005040129A (ja) | 2005-02-17 |
| JP3824619B2 (ja) | 2006-09-20 |
| WO1992008789A1 (en) | 1992-05-29 |
| ITMI913092A1 (it) | 1993-05-20 |
| FR2669346B1 (fr) | 1995-07-21 |
| NL9900036A (nl) | 2003-10-01 |
| ITMI913092A0 (it) | 1991-11-20 |
| GB2283021B (en) | 1995-07-05 |
| GB2264949B (en) | 1995-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5364773A (en) | Genetically engineered vaccine strain | |
| KR970011149B1 (ko) | 재조합 아비폭스 바이러스 | |
| Taylor et al. | Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins | |
| US5843456A (en) | Alvac poxvirus-rabies compositions and combination compositions and uses | |
| US7144578B2 (en) | Poxvirus-rabies recombinants and compositions and methods employing the recombinants | |
| US5756102A (en) | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants | |
| AU672359B2 (en) | Genetically engineered vaccine strain | |
| CA2096633A1 (en) | Measles virus recombinant poxvirus vaccine | |
| JP2007082551A (ja) | 組換えポックスウイルス−カリシウイルス［ウサギ出血疾患ウイルス（ｒｈｄｖ）］組成物および使用 | |
| US5503834A (en) | Measles virus recombinant poxvirus vaccine | |
| WO1996039177A9 (en) | Recombinant poxvirus-calicivirus [rabbit hemorrhagic disease virus (rhdv)] compositions and uses | |
| US5759841A (en) | Immunological composition of measles virus utilizing recombinant poxvirus | |
| EP0623172B1 (en) | Marek's disease virus recombinant vaccinia virus vaccine | |
| AU699903B2 (en) | Measles virus recombinant poxvirus vaccine | |
| CA2187207C (en) | Poxvirus-canine distemper virus (cdv) recombinants and compositions and methods employing the recombinants | |
| AU720448B2 (en) | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants | |
| CA1341403C (en) | Recombinant a vipox virus | |
| Hu | Development of raccoon poxvirus-vectored feline recombinant vaccines | |
| IE60309B1 (en) | Recombinant viruses, vaccines containing them and in vitro cell cultures thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |